DocGo shares declined 0.8% after reporting moderate revenue growth but margin pressures and ongoing losses tempered investor enthusiasm. Despite increasing revenue guidance, investors appeared cautious given continued adjusted EBITDA losses and headwinds from labor costs and rising fuel prices.

• Q1 revenue totaled $75.6 million, driven by growth in virtual care and mobile phlebotomy segments.
• SteadyMD revenue exceeded $9 million with 38% year-over-year visit growth; workforce expanded 45% to address demand.
• Mobile phlebotomy revenue poised for up to 75% growth in 2026, with geographical expansion and technology integration planned.
• Adjusted EBITDA loss was $10.2 million; labor inefficiencies at SteadyMD and higher fuel costs compressed gross margins by approximately 95 basis points combined.
• Revenue guidance raised to $300–315 million for 2026, but adjusted EBITDA guidance maintained at a loss of $5–10 million, signaling cautious outlook on profitability.